Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study

Margaret R. Karagas; Sunyeong Park; Heather H. Nelson; Angeline S. Andrew; Leila Mott; Alan Schned; Karl T. Kelsey

doi:10.1016/j.ijheh.2005.04.005

Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study

Margaret R. Karagas, Sunyeong Park, Heather H. Nelson, Angeline S. Andrew, Leila Mott, Alan Schned, Karl T. Kelsey

Epidemiology & Community Health

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Functional variants in the methylenetetrahydrofolate reductase (MTHFR) gene, including the 677C>T and 1298A>C polymorphisms, have been associated with a moderately reduced risk of several cancers, including colorectal cancers. While recent studies have investigated the role of these polymorphisms on bladder cancer susceptibility, results have been mixed. To clarify the role of MTHFR polymorphisms on bladder cancer risk, we genotyped MTHFR 677C>T and MTHFR 1298A>C in a population-based study of bladder cancer of 352 patients and 551 controls from New Hampshire, USA. The allelic frequency was 35.6% for MTHFR 677C>T and 40.4% for MTHFR 1298A>C among controls. We found no evidence of a main gene effect for either polymorphism (adjusted OR for MTHFR 677C>T variants versus the reference genotype=1.1; 95% CI, 0.8-1.4 and adjusted OR for MTHFR 1298A>C variants versus the reference genotype=1.0; 95% CI, 0.7-1.4). Odds ratios did not appear to differ by smoking status or gender. We observed differences in the risk estimates for the MTHFR polymorphisms by arsenic exposure, but they were not statistically significant (P=0.67 for MTHFR 677C>T and P=0.12 for MTHFR 1298A>C). Thus, our findings do not support the presence of a main gene effect. The possibility that MTHFR polymorphism affects susceptibility to environmental exposures warrants further consideration.

Original language	English (US)
Pages (from-to)	321-327
Number of pages	7
Journal	International Journal of Hygiene and Environmental Health
Volume	208
Issue number	5
DOIs	https://doi.org/10.1016/j.ijheh.2005.04.005
State	Published - Sep 16 2005

Bibliographical note

Funding Information:
Research was supported by Grant numbers 5 P42 ES05947 and ES07373 from the National Institute of Environmental Health Sciences, and CA57494 from the National Cancer Institute, NIH. The authors would like to thank Drs. Joel Schwartz and Zhi-min Yuan for editorial assistance. We are indebted to the staff and participants of the New Hampshire Bladder Cancer Study.

Keywords

Arsenic
Bladder cancer
Case-control study
Gene-environment interaction
Methylenetetrahydrofolate reductase polymorphisms
Smoking

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ijheh.2005.04.005

Find It

Find It at U of M Libraries

Cite this

@article{e115b0c4dab64141bec2c5168e71a5a5,

title = "Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study",

abstract = "Functional variants in the methylenetetrahydrofolate reductase (MTHFR) gene, including the 677C>T and 1298A>C polymorphisms, have been associated with a moderately reduced risk of several cancers, including colorectal cancers. While recent studies have investigated the role of these polymorphisms on bladder cancer susceptibility, results have been mixed. To clarify the role of MTHFR polymorphisms on bladder cancer risk, we genotyped MTHFR 677C>T and MTHFR 1298A>C in a population-based study of bladder cancer of 352 patients and 551 controls from New Hampshire, USA. The allelic frequency was 35.6% for MTHFR 677C>T and 40.4% for MTHFR 1298A>C among controls. We found no evidence of a main gene effect for either polymorphism (adjusted OR for MTHFR 677C>T variants versus the reference genotype=1.1; 95% CI, 0.8-1.4 and adjusted OR for MTHFR 1298A>C variants versus the reference genotype=1.0; 95% CI, 0.7-1.4). Odds ratios did not appear to differ by smoking status or gender. We observed differences in the risk estimates for the MTHFR polymorphisms by arsenic exposure, but they were not statistically significant (P=0.67 for MTHFR 677C>T and P=0.12 for MTHFR 1298A>C). Thus, our findings do not support the presence of a main gene effect. The possibility that MTHFR polymorphism affects susceptibility to environmental exposures warrants further consideration.",

keywords = "Arsenic, Bladder cancer, Case-control study, Gene-environment interaction, Methylenetetrahydrofolate reductase polymorphisms, Smoking",

author = "Karagas, {Margaret R.} and Sunyeong Park and Nelson, {Heather H.} and Andrew, {Angeline S.} and Leila Mott and Alan Schned and Kelsey, {Karl T.}",

note = "Funding Information: Research was supported by Grant numbers 5 P42 ES05947 and ES07373 from the National Institute of Environmental Health Sciences, and CA57494 from the National Cancer Institute, NIH. The authors would like to thank Drs. Joel Schwartz and Zhi-min Yuan for editorial assistance. We are indebted to the staff and participants of the New Hampshire Bladder Cancer Study.",

year = "2005",

month = sep,

day = "16",

doi = "10.1016/j.ijheh.2005.04.005",

language = "English (US)",

volume = "208",

pages = "321--327",

journal = "International Journal of Hygiene and Environmental Health",

issn = "1438-4639",

publisher = "Elsevier GmbH",

number = "5",

}

TY - JOUR

T1 - Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer

T2 - A population-based case-control study

AU - Karagas, Margaret R.

AU - Park, Sunyeong

AU - Nelson, Heather H.

AU - Andrew, Angeline S.

AU - Mott, Leila

AU - Schned, Alan

AU - Kelsey, Karl T.

N1 - Funding Information: Research was supported by Grant numbers 5 P42 ES05947 and ES07373 from the National Institute of Environmental Health Sciences, and CA57494 from the National Cancer Institute, NIH. The authors would like to thank Drs. Joel Schwartz and Zhi-min Yuan for editorial assistance. We are indebted to the staff and participants of the New Hampshire Bladder Cancer Study.

PY - 2005/9/16

Y1 - 2005/9/16

N2 - Functional variants in the methylenetetrahydrofolate reductase (MTHFR) gene, including the 677C>T and 1298A>C polymorphisms, have been associated with a moderately reduced risk of several cancers, including colorectal cancers. While recent studies have investigated the role of these polymorphisms on bladder cancer susceptibility, results have been mixed. To clarify the role of MTHFR polymorphisms on bladder cancer risk, we genotyped MTHFR 677C>T and MTHFR 1298A>C in a population-based study of bladder cancer of 352 patients and 551 controls from New Hampshire, USA. The allelic frequency was 35.6% for MTHFR 677C>T and 40.4% for MTHFR 1298A>C among controls. We found no evidence of a main gene effect for either polymorphism (adjusted OR for MTHFR 677C>T variants versus the reference genotype=1.1; 95% CI, 0.8-1.4 and adjusted OR for MTHFR 1298A>C variants versus the reference genotype=1.0; 95% CI, 0.7-1.4). Odds ratios did not appear to differ by smoking status or gender. We observed differences in the risk estimates for the MTHFR polymorphisms by arsenic exposure, but they were not statistically significant (P=0.67 for MTHFR 677C>T and P=0.12 for MTHFR 1298A>C). Thus, our findings do not support the presence of a main gene effect. The possibility that MTHFR polymorphism affects susceptibility to environmental exposures warrants further consideration.

AB - Functional variants in the methylenetetrahydrofolate reductase (MTHFR) gene, including the 677C>T and 1298A>C polymorphisms, have been associated with a moderately reduced risk of several cancers, including colorectal cancers. While recent studies have investigated the role of these polymorphisms on bladder cancer susceptibility, results have been mixed. To clarify the role of MTHFR polymorphisms on bladder cancer risk, we genotyped MTHFR 677C>T and MTHFR 1298A>C in a population-based study of bladder cancer of 352 patients and 551 controls from New Hampshire, USA. The allelic frequency was 35.6% for MTHFR 677C>T and 40.4% for MTHFR 1298A>C among controls. We found no evidence of a main gene effect for either polymorphism (adjusted OR for MTHFR 677C>T variants versus the reference genotype=1.1; 95% CI, 0.8-1.4 and adjusted OR for MTHFR 1298A>C variants versus the reference genotype=1.0; 95% CI, 0.7-1.4). Odds ratios did not appear to differ by smoking status or gender. We observed differences in the risk estimates for the MTHFR polymorphisms by arsenic exposure, but they were not statistically significant (P=0.67 for MTHFR 677C>T and P=0.12 for MTHFR 1298A>C). Thus, our findings do not support the presence of a main gene effect. The possibility that MTHFR polymorphism affects susceptibility to environmental exposures warrants further consideration.

KW - Arsenic

KW - Bladder cancer

KW - Case-control study

KW - Gene-environment interaction

KW - Methylenetetrahydrofolate reductase polymorphisms

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=23944519853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944519853&partnerID=8YFLogxK

U2 - 10.1016/j.ijheh.2005.04.005

DO - 10.1016/j.ijheh.2005.04.005

M3 - Article

C2 - 16217917

AN - SCOPUS:23944519853

SN - 1438-4639

VL - 208

SP - 321

EP - 327

JO - International Journal of Hygiene and Environmental Health

JF - International Journal of Hygiene and Environmental Health

IS - 5

ER -

Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this